Vascular calcifications: pathogenesis, management, and impact on clinical outcomes.
The predisposition to vascular calcifications in patients with chronic kidney disease (CKD) has gained great interest in recent years as many studies have described its likely impact on morbidity and mortality. The mechanism by which the process of vascular calcification is produced is complex, and it does not consist in a simple precipitation of calcium and phosphate but is instead an active and modifiable process. Several "modifiable and nonmodifiable" factors that are able to promote vascular calcification are extremely frequent in patients with CKD. Most of the present strategies to decrease vascular calcifications are based in the control of the more prevalent modifiable risk factors. Unfortunately, the extremely important nonmodifiable risk factors, which are highly prevalent, such as older age, time on dialysis, and diabetes, are not under one's control. Recent studies also have shown that vascular calcifications in some localizations were associated with increased osteoporotic fractures not only in dialysis patients but also in the general population, and interestingly, mortality also was associated significantly and positively with vascular calcifications and nontraumatic bone fractures. Despite that new strategies may improve the management of vascular diseases and specifically have a positive impact on the high prevalence of vascular calcifications, still the best possible control of the bone metabolic and inflammatory parameters are in the primary line. The horizon of the coming decade looks promising, but solid clinical and epidemiologic data are needed to manage better the bone- and cardiovascular-related disorders in patients with CKD.
Cannata-Andía
Jorge B
JB
Bone and Mineral Research Unit, Instituto Reina Sofía de Investigacíon, Hospital Universitario Central de Asturias, Universidad de Oviedo, Julián Clavería S/N, Oviedo 33006, Spain. cannata@hca.es
Rodríguez-García
Minerva
M
Carrillo-López
Natalia
N
Naves-Díaz
Manuel
M
Díaz-López
Bernardino
B
D015519:Bone Density / Q000502:physiology; D002114:Calcinosis / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D002908:Chronic Disease; D006801:Humans; D007674:Kidney Diseases / Q000150:complications* / Q000503:physiopathology; D010024:Osteoporosis / Q000209:etiology / Q000503:physiopathology; D012307:Risk Factors; D014652:Vascular Diseases / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology